Cancer - Bladder, Pelvis, Ureter & Others(구연) Oral Session 5 / Cancer - Bladder, Pelvis, Ureter & Others (Ⅰ) (O-050) Rm.201 10월 30일(수) 15:00-16:00 비침윤성 방광암 환자에서 Bacillus-Calmette-Guerin 투여후 유발된 전립선염에 대한 위험 인자 분석 CHA의과학대학교 분당차병원¹비뇨의학과 교실 분당서울대학교병원 김태진¹, 유영동¹, 박동수¹, 홍성규², 변석수², 이상은², 오종진² Purpose To evaluate risk factors for bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer following bacillus Calmette–Guerin therapy. Materials and Methods Clinical findings from patients with non-muscle invasive bladder cancer who underwent multi-parametric magnetic resonance imaging before transurethral resection of bladder tumor and post-bacillus Calmette–Guerin therapy between March 2004 to August 2018 were evaluated. The population was grouped into patients with or without newly developed lesions on multi-parametric magnetic resonance imaging performed 3 months after bacillus Calmette–Guerin instillation. Patients with prostate-specific antigen levels >2 ng/mL or prostate cancer were excluded. Univariate and multivariate analyses were performed to determine the predictors of prostate lesions in patients with prior bacillus Calmette–Guerin exposure. Results Post bacillus Calmette–Guerin-induced prostatitis was found in 50 of the 194 patients (25.8%). No significant differences were observed between the groups except for prostate volumes (33.8 mL vs. 30.8 mL, P=0.012) and body mass index (25.2 kg/m2 vs. 24.1 kg/m2, P=0.044). After bacillus Calmette–Guerin exposure, no significant clinical differences in prostate-specific antigen levels, international prostate symptom scores, or post-voiding residual volume were noted. Multivariate regression analysis showed that body mass index (odds ratio, OR=1.113, P=0.033) and prostate volume (OR=3.080, P=0.012) were significant predictors of post-bacillus Calmette–Guerin prostate lesions. Conclusions Body mass index and prostate volume may be clinical predictors of prostate lesions after bacillus Calmette–Guerin exposure. Awareness of potential risk factors for this entity should contribute to the clinical decision-making process for patients following bacillus Calmette–Guerin therapy. keywords : BCG, Prostate, Prostatitis